Lurbinectedin Mechanisim of Action

GC32834 Lurbinectedin (PM01183) 497871-47-3Подробнее

Lurbinectedin in BRCA 1/2 breast cancerПодробнее

Lurbinectedin in SCLCПодробнее

Badri Rengarajan, MD: Lurbinectedin (Zepzelca)Подробнее

Facilitating Progress in the Treatment of SCLCПодробнее

Halaven MOAПодробнее

Dr. West on Lurbinectedin in SCLCПодробнее

Dr. Forster on Recent Data With Lurbinectedin in SCLCПодробнее

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLCПодробнее

Novel Therapies In Small Cell Lung Cancer (SCLC): LurbinectedinПодробнее

Findings from ATLANTIS: lurbinectedin/doxorubicin vs topotecan or CAV in SCLCПодробнее

Tagraxofusp Mechanism of ActionПодробнее

Current Controversies in Small Cell Lung Cancer (SCLC)Подробнее

LUPER: lurbinectedin in combination with pembrolizumab in relapsed SCLCПодробнее

Dr. Forster on Next Steps With Lurbinectedin in SCLCПодробнее

Lurbinectedin’s Role in Managing SCLCПодробнее

Lurbinectedin Efficacy & Safety HighlightsПодробнее

Palliative radiotherapy with lurbinectedin in patients with extensive stage SCLCПодробнее

Lurbinectedin for Second Line Treatment of Small Cell Lung CancerПодробнее